THE RESISTANCE OF CANCER CELLS TO PALBOCICLIB, A CYCLIN-DEPENDENT KINASE 4/6 INHIBITOR, IS MEDIATED BY THE ABCB1 TRANSPORTER

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

Palbociclib was approved Treatments - Cold by the United States Food and Drug Administration for use, in combination with letrozole, as a first-line treatment for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) postmenopausal metastatic breast cancer.However, recent studies show that palbociclib may be an in

read more


VHL mutation drives human clear cell renal cell carcinoma progression through PI3K/AKT-dependent cholesteryl ester accumulationResearch in context

Summary: Background: Cholesteryl ester (CE) accumulation in intracellular lipid droplets (LDs) is an essential signature of clear cell renal cell carcinoma (ccRCC), but its molecular mechanism and pathological significance remain elusive.Methods: Enabled by the label-free Raman spectromicroscopy, which integrated stimulated Raman scattering microsc

read more